Brendt has over 19 years’ experience in the pharmaceutical and CRO industry and has extensive experience in pre-clinical, early development, and end-to-end drug development, specializing in clinical development planning and target product profiling. He served 13 years at GSK as a clinical program lead where he designed and implemented both early and late phase clinical trials. Brendt joined PriceWaterhouseCoopers’ health industry advisory team in 2015 as a senior associate helping clients develop solutions to decrease drug development timelines. In 2016, he joined the PPD Consulting team where he helped PPD clients with their clinical development needs and planning.
Brendt earned a bachelor’s degree in biology from The Pennsylvania State University and a master’s degree in pharmacology from Thomas Jefferson University. He is currently pursuing a master’s in business administration at Sellinger School of Business at Loyola University, Maryland.